Literature DB >> 22041710

Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.

Jenny Welander1, Peter Söderkvist, Oliver Gimm.   

Abstract

Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare neuroendocrine tumors of the adrenal glands and the sympathetic and parasympathetic paraganglia. They can occur sporadically or as a part of different hereditary tumor syndromes. About 30% of PCCs and PGLs are currently believed to be caused by germline mutations and several novel susceptibility genes have recently been discovered. The clinical presentation, including localization, malignant potential, and age of onset, varies depending on the genetic background of the tumors. By reviewing more than 1700 reported cases of hereditary PCC and PGL, a thorough summary of the genetics and clinical features of these tumors is given, both as part of the classical syndromes such as multiple endocrine neoplasia type 2 (MEN2), von Hippel-Lindau disease, neurofibromatosis type 1, and succinate dehydrogenase-related PCC-PGL and within syndromes associated with a smaller fraction of PCCs/PGLs, such as Carney triad, Carney-Stratakis syndrome, and MEN1. The review also covers the most recently discovered susceptibility genes including KIF1Bβ, EGLN1/PHD2, SDHAF2, TMEM127, SDHA, and MAX, as well as a comparison with the sporadic form. Further, the latest advances in elucidating the cellular pathways involved in PCC and PGL development are discussed in detail. Finally, an algorithm for genetic testing in patients with PCC and PGL is proposed.

Entities:  

Mesh:

Year:  2011        PMID: 22041710     DOI: 10.1530/ERC-11-0170

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  114 in total

1.  Pheochromocytoma Due to TMEM127 Mutation - The Importance of Genetic Testing for Clinical Decision.

Authors:  Sílvia Cristina de Sousa Paredes; Sara Gomes de Campos Lopes; Isabel Maria Beleza Ferraz Torres; Marta de Lurdes Fernandes Alves
Journal:  Eur Endocrinol       Date:  2020-04-01

Review 2.  Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.

Authors:  Thamara E Osinga; Thera P Links; Robin P F Dullaart; Karel Pacak; Anouk N A van der Horst-Schrivers; Michiel N Kerstens; Ido P Kema
Journal:  FASEB J       Date:  2017-03-06       Impact factor: 5.191

Review 3.  An update on the genetics of pheochromocytoma.

Authors:  D Karasek; U Shah; Z Frysak; C Stratakis; K Pacak
Journal:  J Hum Hypertens       Date:  2012-05-31       Impact factor: 3.012

Review 4.  Next-generation sequencing for the diagnosis of hereditary pheochromocytoma and paraganglioma syndromes.

Authors:  Rodrigo A Toledo; Patricia L M Dahia
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-06       Impact factor: 3.243

Review 5.  Primary cardiac tumors associated with genetic syndromes: a comprehensive review.

Authors:  Elizabeth Lee; Maryam Ghadimi Mahani; Jimmy C Lu; Adam L Dorfman; Ashok Srinivasan; Prachi P Agarwal
Journal:  Pediatr Radiol       Date:  2017-12-06

Review 6.  Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management.

Authors:  Amrish Jain; Rossana Baracco; Gaurav Kapur
Journal:  Pediatr Nephrol       Date:  2019-01-02       Impact factor: 3.714

7.  Role of SDHAF2 and SDHD in von Hippel-Lindau associated pheochromocytomas.

Authors:  Johan Kugelberg; Jenny Welander; Francesca Schiavi; Ambrogio Fassina; Martin Bäckdahl; Catharina Larsson; Giuseppe Opocher; Peter Söderkvist; Patricia L Dahia; Hartmut P H Neumann; Oliver Gimm
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

8.  Urapidil in the preoperative treatment of pheochromocytomas: a safe and cost-effective method.

Authors:  Nils Habbe; Florian Ruger; Jorg Bojunga; Wolf Otto Bechstein; Katharina Holzer
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

9.  Functional paraganglioma.

Authors:  Gokulakrishnan Balasubramanian; Vallikantha Nellaiappan
Journal:  BMJ Case Rep       Date:  2014-02-20

10.  Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas.

Authors:  Esmeralda Castelblanco; Maria Santacana; Joan Valls; Aguirre de Cubas; Alberto Cascón; Mercedes Robledo; Xavier Matias-Guiu
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.